Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.

Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, Krebsbach C, Patel RP, Karki C, Rosmarin D.

Dermatol Ther (Heidelb). 2019 Oct 19. doi: 10.1007/s13555-019-00334-1. [Epub ahead of print]

PMID:
31630336
2.

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.

Guenther L, Potts Bleakman A, Weisman J, Poulin Y, Spelman L, Burge R, Erickson J, Todd K, Bertram CC, Ryan C.

Acta Derm Venereol. 2019 Oct 17. doi: 10.2340/00015555-3353. [Epub ahead of print]

3.

Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignahi F, Thyssen JP, Burge R, Mallbris L.

J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print] Review.

PMID:
31465593
4.

Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis.

Yosipovitch G, Dong Y, Burge R, Zhu B, Shrom D, Kimball AB.

Acta Derm Venereol. 2019 Jul 10. doi: 10.2340/00015555-3254. [Epub ahead of print] No abstract available.

5.

Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses.

Armstrong AW, Edson-Heredia E, Naegeli AN, Burge R, Poon JL, Anatchkova M, Sun L, Zhu B, Wyrwich KW.

J Dermatolog Treat. 2019 Jul 15:1-8. doi: 10.1080/09546634.2019.1623370. [Epub ahead of print]

PMID:
31157576
6.

Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study.

Tekin HG, Wu JJ, Burge R, Birt J, Egeberg A.

J Rheumatol. 2019 Jul;46(7):716-720. doi: 10.3899/jrheum.180670. Epub 2019 Mar 1.

PMID:
30824662
7.

Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis.

Andersen YMF, Augustin M, Petersen J, Hagenström K, Mallbris L, Burge R, Egeberg A.

Br J Dermatol. 2019 Feb 28. doi: 10.1111/bjd.17832. [Epub ahead of print]

PMID:
30815849
8.

Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.

Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A.

J Dermatolog Treat. 2019 Feb 25:1-6. doi: 10.1080/09546634.2019.1587146. [Epub ahead of print]

PMID:
30799638
9.

Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS).

Chen CH, Elsalmawy AH, Ish-Shalom S, Lim SJ, Al-Ali NS, Cunha-Borges JL, Yang H, Casas N, Altan L, Moll T, Gurbuz S, Brnabic AJM, Burge RT, Marin F.

Curr Med Res Opin. 2019 Jun;35(6):1041-1049. doi: 10.1080/03007995.2018.1552576. Epub 2019 Jan 3.

PMID:
30474449
10.

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.

Yosipovitch G, Foley P, Ryan C, Cather JC, Meeuwis KA, Burge R, Bleakman AP, Lin CY, Malatestinic W, Gottlieb A.

J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004.

11.

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.

Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB.

Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508. eCollection 2018. Review.

13.

Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.

Wu JJ, Lin C, Sun L, Goldblum O, Zbrozek A, Burge R, Augustin M, Feldman SR.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):318-324. doi: 10.1111/jdv.15098. Epub 2018 Jun 26.

PMID:
29846976
14.

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.

PMID:
29747232
15.

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.

Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G.

J Am Acad Dermatol. 2018 Aug;79(2):294-301.e6. doi: 10.1016/j.jaad.2018.03.047. Epub 2018 Apr 10.

PMID:
29653208
16.

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A.

J Invest Dermatol. 2018 Sep;138(9):1955-1961. doi: 10.1016/j.jid.2018.01.041. Epub 2018 Mar 22.

17.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Sep;79(3):593-595. doi: 10.1016/j.jaad.2018.03.008. Epub 2018 Mar 17. No abstract available.

PMID:
29559395
18.

Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.

Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM.

J Drugs Dermatol. 2017 Dec 1;16(12):1246-1252.

PMID:
29240860
19.

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Cather J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):33-44. doi: 10.1007/s13555-017-0212-3. Epub 2017 Dec 4.

20.

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Yosipovitch G.

Dermatol Ther (Heidelb). 2018 Mar;8(1):45-56. doi: 10.1007/s13555-017-0213-2. Epub 2017 Dec 4.

21.

Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.

Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O.

J Manag Care Spec Pharm. 2017 Nov;23(11):1178-1190. doi: 10.18553/jmcp.2017.17054. Epub 2017 Aug 22.

22.

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.

Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Burge R, Lin CY, Yosipovitch G.

Acta Derm Venereol. 2018 Jan 12;98(1):98-102. doi: 10.2340/00015555-2801.

23.

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.

Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72. doi: 10.1111/jdv.14581. Epub 2017 Oct 6.

PMID:
28881462
24.

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.

Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C.

J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22.

PMID:
28760056
25.

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.

Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P.

J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4.

PMID:
28573743
26.

Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.

Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O.

Osteoporos Int. 2017 Aug;28(8):2485-2494. doi: 10.1007/s00198-017-4072-6. Epub 2017 May 23.

27.

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.

Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1483-1490. doi: 10.1111/jdv.14211. Epub 2017 Jun 28.

PMID:
28294430
28.

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. Erratum in: J Eur Acad Dermatol Venereol. 2017 Oct;31(10 ):1764.

29.

Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.

Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH.

Osteoporos Int. 2017 Mar;28(3):799-809. doi: 10.1007/s00198-016-3888-9. Epub 2016 Dec 27.

30.

Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review.

Sugimoto T, Sato M, Dehle FC, Brnabic AJ, Weston A, Burge R.

Value Health Reg Issues. 2016 May;9:49-56. doi: 10.1016/j.vhri.2015.09.005. Epub 2015 Dec 4. Review.

PMID:
27881259
31.

Real-world clinical and economic outcomes for daily teriparatide patients in Japan.

Burge R, Sato M, Sugihara T.

J Bone Miner Metab. 2016 Nov;34(6):692-702. Epub 2015 Dec 10.

PMID:
26661475
32.

Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.

Chan DC, Chang CH, Lim LC, Brnabic AJM, Tsauo JY, Burge R, Hsiao FY, Jin L, Gürbüz S, Yang RS.

Osteoporos Int. 2016 Sep;27(9):2855-2865. doi: 10.1007/s00198-016-3611-x. Epub 2016 May 12.

33.

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.

Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, Krohn KD, Warner MR, Ahmad QI, Mitlak B.

Clin Orthop Relat Res. 2016 May;474(5):1234-44. doi: 10.1007/s11999-015-4669-z. Epub 2016 Mar 1.

34.
35.

Neurobehavioral impairments produced by developmental lead exposure persisted for generations in zebrafish (Danio rerio).

Xu X, Weber D, Burge R, VanAmberg K.

Neurotoxicology. 2016 Jan;52:176-85. doi: 10.1016/j.neuro.2015.12.009. Epub 2015 Dec 10.

PMID:
26688331
36.

Posthospital Discharge Medical Care Costs and Family Burden Associated with Osteoporotic Fracture Patients in China from 2011 to 2013.

Xie Z, Burge R, Yang Y, Du F, Lu T, Huang Q, Ye W, Xu W.

J Osteoporos. 2015;2015:258089. doi: 10.1155/2015/258089. Epub 2015 Jun 28.

37.

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.

Osteoporos Int. 2015 Nov;26(11):2677-84. doi: 10.1007/s00198-015-3173-3. Epub 2015 Jun 20.

38.

Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis.

Yang Y, Du F, Ye W, Chen Y, Li J, Zhang J, Nicely H, Burge R.

Clinicoecon Outcomes Res. 2015 Apr 13;7:205-12. doi: 10.2147/CEOR.S77175. eCollection 2015.

39.

Teriparatide fracture effectiveness in the real world.

Krege JH, Burge RT, Marin F.

Osteoporos Int. 2015 Aug;26(8):2217-8. doi: 10.1007/s00198-015-3140-z. Epub 2015 Apr 24. No abstract available.

PMID:
25906242
40.

Clinical and economic characteristics of total hip replacement patients with high health care costs and high health care use.

Cui Z, Schoenfeld M, Chen Y, Bush EN, Burge R.

Am J Phys Med Rehabil. 2015 Apr;94(4):269-79. doi: 10.1097/PHM.0000000000000154.

PMID:
25785921
41.

Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study.

Shen W, Burge R, Naegeli AN, Shih J, Alam J, Gold DT, Silverman S.

BMC Musculoskelet Disord. 2014 Nov 17;15:374. doi: 10.1186/1471-2474-15-374.

42.

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).

Fujiwara S, Hamaya E, Sato M, Graham-Clarke P, Flynn JA, Burge R.

Clin Interv Aging. 2014 Nov 5;9:1879-93. doi: 10.2147/CIA.S70307. eCollection 2014. Review.

43.

Metabolic Disorders, Osteoporosis and Fracture Risk in Asia: A Systematic Review.

Sugimoto T, Sato M, Dehle FC, Brnabic AJ, Weston AR, Burge RT.

Value Health. 2014 Nov;17(7):A772. doi: 10.1016/j.jval.2014.08.323. Epub 2014 Oct 26. No abstract available.

44.

Outcomes in Severe Osteoporotic Women in Korea Using Sequential Treatment.

Kim BR, Burge R, Klein TM, Smolen LJ.

Value Health. 2014 Nov;17(7):A771. doi: 10.1016/j.jval.2014.08.317. Epub 2014 Oct 26. No abstract available.

45.

Can bundled payment improve quality and efficiency of care for patients with hip fractures?

Antonova E, Boye ME, Sen N, O'Sullivan AK, Burge R.

J Aging Soc Policy. 2015;27(1):1-20. doi: 10.1080/08959420.2015.970844.

PMID:
25299851
46.

Characteristics of hip fracture patients with and without muscle atrophy/weakness: predictors of negative economic outcomes.

Cui Z, Schoenfeld MJ, Bush EN, Chen Y, Burge R.

J Med Econ. 2015 Jan;18(1):1-11. doi: 10.3111/13696998.2014.969433. Epub 2014 Oct 8.

PMID:
25271379
47.

Retrospective database study to assess the economic impact of hip fracture in the United Kingdom.

Lambrelli D, Burge R, Raluy-Callado M, Chen SY, Wu N, Schoenfeld MJ.

J Med Econ. 2014 Nov;17(11):817-25. doi: 10.3111/13696998.2014.959588. Epub 2014 Sep 12.

PMID:
25164473
48.

Texting while driving: is speech-based text entry less risky than handheld text entry?

He J, Chaparro A, Nguyen B, Burge RJ, Crandall J, Chaparro B, Ni R, Cao S.

Accid Anal Prev. 2014 Nov;72:287-95. doi: 10.1016/j.aap.2014.07.014. Epub 2014 Aug 2.

PMID:
25089769
49.

Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function.

Nixon A, Kerr C, Doll H, Naegeli AN, Shingler SL, Breheny K, Burge R, Gold DT, Silverman S.

Osteoporos Int. 2014 Jun;25(6):1775-84. doi: 10.1007/s00198-014-2695-4. Epub 2014 Apr 16.

50.

Structural characterization of interactions between the double-stranded RNA-binding zinc finger protein JAZ and nucleic acids.

Burge RG, Martinez-Yamout MA, Dyson HJ, Wright PE.

Biochemistry. 2014 Mar 11;53(9):1495-510. doi: 10.1021/bi401675h. Epub 2014 Feb 27.

Supplemental Content

Support Center